INDV.L

Indivior PLC [INDV.L] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

INDV.L Stock Summary

Top 10 Correlated ETFs

INDV.L

Top 10 Correlated Stocks

INDV.L

In the News

INDV.L Financial details

Company Rating
-
Market Cap
2.12B
Income
2M
Revenue
1.09B
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
1.16K
Optionable
No
Shortable
Yes
Earnings
22 Feb 2024
P/E
-8.94
Forward P/E
-
PEG
4.25
P/S
2
P/B
-87.54
P/C
-
P/FCF
-23.4
Quick Ratio
0.82
Current Ratio
0.98
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.3
EPS next Y
-
EPS next Q
-
EPS this Y
-102.63%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-59.52%
Revenue last 5Y
6.84%
Revenue Q/Q
8.12%
EPS Q/Q
-
-
-
-
-
SMA20
11.02%
SMA50
45.71%
SMA100
38.24%
Inst Own
-
Inst Trans
-
ROA
-13%
ROE
-435%
ROC
-0.49%
Gross Margin
83%
Oper. Margin
-29%
Profit Margin
-23%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1125.0-1938.0
52W High
-41.64%
52W Low
+0.53%
RSI
65.51
Rel Volume
0.25
Avg Volume
496.76K
Volume
123.18K
Perf Week
5.8%
Perf Month
24.56%
Perf Quarter
18.37%
Perf Half Y
14.94%
-
-
-
-
Beta
0.018
-
-
Volatility
11.07%, 58.2%
Prev Close
2.26%
Price
1131
Change
2.54%

Something similar

Top by Market Cap
LLY.SW
BRH.DE
TSLA
NVDA
DHR-PB
Top Correlated ETFs
EHBA.DE
EHYB.L
HDGB.L
WBIO.L
HDRO.L
Top Correlated Stocks
7564.T
7504.T
8392.T
OCI.L
6269.T
Similar Market Cap
XAIX.DE
003010.SZ
603616.SS
8429.TW
3540.TWO

Company Profile

Healthcare Drug Manufacturers - Specialty & Generic
  • Volume Average 496.76K
  • Market Capitalization 2.12B
  • Employee 1.16K
  • CEO Mr. Mark Crossley
  • Headquarters North Chesterfield,VA,US
  • IPO Date 2014-12-22
  • Website https://www.indivior.com

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.